HomeAI · summaries
Storia in 5 fonti
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Novartis' Phase 3 cardiovascular study miss raises the stakes for Amgen, Lilly
Novartis' pelacarsen fails Lp(a)HORIZON, the third major CV outcomes trial miss in two months, as Amgen, Lilly and others push ahead.
- ·
healio.com
‘Not the results we hoped for’: Lp(a)-lowering drug pelacarsen fails to reduce CV events
The Lp(a)HORIZON trial of pelacarsen, the first cardiovascular outcomes trial for an agent designed to lower lipoprotein(a), failed to achieve its primary outcome, Novartis…
